Chief Development Officer
Dr. Rebecca Juliano is a seasoned pharmaceutical R&D executive with scientific and development expertise in preclinical and clinical omega-3 fatty acid research. Most recently, Dr. Juliano served as the SVP of Clinical R&D at Amarin Pharma, where she led the Clinical Development/Operations and Biostatistics & Data Management teams who successfully completed the REDUCE-IT cardiovascular outcomes study with the omega-3 therapeutic Vascepa and actively supported global regulatory approvals. In an earlier role, Dr. Juliano supported the launch of the omega-3 therapeutic Omacor/Lovaza at Reliant Pharmaceuticals. Dr. Juliano earned a degree in Chemistry from the University of California at Santa Cruz, followed by an MA, MPhil, and PhD in Nutritional Biochemistry from Columbia University in New York City, and an American Heart Association fellowship for postdoctoral research at Weill Cornell Medical Center in New York City.